Your browser doesn't support javascript.
loading
BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer.
Adeegbe, Dennis O; Liu, Shengwu; Hattersley, Maureen M; Bowden, Michaela; Zhou, Chensheng W; Li, Shuai; Vlahos, Raven; Grondine, Michael; Dolgalev, Igor; Ivanova, Elena V; Quinn, Max M; Gao, Peng; Hammerman, Peter S; Bradner, James E; Diehl, J Alan; Rustgi, Anil K; Bass, Adam J; Tsirigos, Aristotelis; Freeman, Gordon J; Chen, Huawei; Wong, Kwok-Kin.
Afiliación
  • Adeegbe DO; Laura & Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, New York. Kwok-Kin.Wong@nyumc.org Dennis.Adeegbe@nyumc.org.
  • Liu S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Hattersley MM; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Bowden M; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts.
  • Zhou CW; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Li S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Vlahos R; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Grondine M; Department of Pathology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
  • Dolgalev I; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Ivanova EV; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts.
  • Quinn MM; Applied Bioinformatics Laboratories and Department of Pathology, New York University School of Medicine, New York, New York.
  • Gao P; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Hammerman PS; Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Bradner JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Diehl JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Rustgi AK; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Bass AJ; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Tsirigos A; Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.
  • Freeman GJ; Division of Gastroenterology, Departments of Medicine and Genetics, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
  • Chen H; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Wong KK; Applied Bioinformatics Laboratories and Department of Pathology, New York University School of Medicine, New York, New York.
Cancer Immunol Res ; 6(10): 1234-1245, 2018 10.
Article en En | MEDLINE | ID: mdl-30087114
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Azepinas / Triazoles / Proteínas Nucleares / Carcinoma de Pulmón de Células no Pequeñas / Receptor de Muerte Celular Programada 1 / Neoplasias Pulmonares Límite: Animals Idioma: En Revista: Cancer Immunol Res Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Azepinas / Triazoles / Proteínas Nucleares / Carcinoma de Pulmón de Células no Pequeñas / Receptor de Muerte Celular Programada 1 / Neoplasias Pulmonares Límite: Animals Idioma: En Revista: Cancer Immunol Res Año: 2018 Tipo del documento: Article